Good price  online

products details

Created with Pixso. Home Created with Pixso. Products Created with Pixso.
Gastrointestinal Cancer Treatment
Created with Pixso. Lenvatinib Mesilate Capsules 4mg 30 Capsules Box Multi Kinase TKI for Thyroid Hepatocellular Renal Cell Carcinoma

Lenvatinib Mesilate Capsules 4mg 30 Capsules Box Multi Kinase TKI for Thyroid Hepatocellular Renal Cell Carcinoma

Brand Name: Sichuan Kelun Pharmaceutical Co., Ltd.
Model Number: Lenvatinib KL-20213946
MOQ: Negotiable
Price: Please contact a specialist WhatsApp:55342706
Delivery Time: Negotiable
Payment Terms: Western Union,MoneyGram,T/T
Detail Information
Place of Origin:
Chengdu, Sichuan, China
Certification:
NMPA/GMP
Packaging Details:
Negotiable
Supply Ability:
Negotiable
Highlight:

Multi Kinase VEGFR TKI

,

Differentiated Thyroid Cancer Therapy

,

HCC RCC Oral Capsule Treatment

Product Description

Lenvatinib Mesilate 4mg x 30 Capsules

[Product Name]

Generic Name: Lenvatinib Mesilate

Brand Name: Lundaxin

Specification: 4mg x 30 Capsules

[Active Ingredient]

Lenvatinib Mesilate

[Indications]

1. Radioactive iodine-refractory differentiated thyroid cancer. 2. First-line unresectable HCC. 3. Advanced RCC with everolimus.

[Mechanism of Action]

Multi-targeted TKI inhibiting VEGFR1-3, FGFR1-4, PDGFRa, c-KIT, RET. Dual anti-angiogenic and direct antitumor activity.

[Dosage and Administration]

DTC: 24mg daily. HCC: 8mg (<60kg) or 12mg (>=60kg) daily. RCC: 18mg with everolimus. Dose modify in 4mg increments.

[Adverse Reactions]

Hypertension (73%), fatigue, diarrhea (67%), decreased appetite, hand-foot syndrome, proteinuria. Cardiac dysfunction, hepatotoxicity, hemorrhage, RPLS.

[Storage]

Store below 30C. Keep out of reach of children.

[Shelf Life]

24 months

Approval: H20213946